-
Etoricoxib, sold
under the
brand name Arcoxia, is a
selective COX-2
inhibitor developed and
commercialized by Merck. It is
approved in 63
countries worldwide...
- in the
United States. In the
European Union, celecoxib, parecoxib, and
etoricoxib have been
approved for use by the
European Medicines Agency. Paracetamol...
-
gastrointestinal tract.
Selectivity for COX-2 is the main
feature of celecoxib,
etoricoxib, and
other members of this drug class.
Because COX-2 is
usually specific...
-
Clarithromycin Cotrimoxazole Doxycycline Fluconazole NSAIDs (e.g., ibuprofen,
etoricoxib, naproxen)
Phenytoin Pseudoephedrine Trimethoprim Drug
eruption List of...
-
there was no
significant difference between NSAIDs. It was
concluded that
etoricoxib was more
effective in
reducing pain of AS,
however due to
small studies...
-
versions in general).
These drugs (such as rofecoxib, celecoxib, and
etoricoxib) are
equally effective analgesics when
compared with NSAIDs, but cause...
-
substituent (SO2NH2) in para-position on one of the aryl
rings while etoricoxib and
rofecoxib have a
methylsulfone (SO2CH3). The
oxidation state on the...
-
Sulindac Tolmetin Zomepirac ‡ COX-2
inhibitors Celecoxib (+tramadol)
Etoricoxib Lumiracoxib ‡
Parecoxib Rofecoxib ‡
Valdecoxib ‡
Fenamates Flufenamic...
- University. At Merck, she
became the
chief statistician on the
Multinational Etoricoxib and
Diclofenac Arthritis Long-term (MEDAL) programme, a
large international...
- from PubChem)
Emylcamate Enflurane Entacapone Escitalopram Etomidate Etoricoxib Ethosuximide Levophacetoperane Phenprobamate Phenaglycodol Phenelzine...
